University of Michigan's Risk Science Center offers a quick and handy explanation of the FDA's recent crackdown on personal genomics company 23andme. Some clean, even-keeled perspective to be had here. For more, see these musings from genomics expert (and member of 23andme's Scientific Advisory Board) Mike Eisen.
Kinja is in read-only mode. We are working to restore service.